Back

Hypertrophic obstructive cardiomyopathy and magnetic resonance imaging: exploring the impact of mavacamten

9 May 2026 (11:30 - 12:15)
Organised by: Logo
Congress Presentation Part of: Implementing integrated care pathways in heart failure Imaging HFA Premium Access Heart Failure 2026 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Anna Aigner

Kepler University Hospital Linz, Linz (Austria)

6 More presentations in this session

Presentation thumbnail
Factors associated with non-fatal discontinuation of a heart failure self-monitoring program in a rural super-aging japanese city
Mr K. Yonezu (Yufu City, JP)
Abstract Slides Video
Presentation thumbnail
Bridging the gap between guidelines and clinical practice: the use of an online multidisciplinary heart failure care pathway in Belgium and beyond.
Doctor D. Derthoo (Kortrijk, BE)
Abstract Slides Video
Presentation thumbnail
Rapid inpatient guideline-directed medical therapy implementation for heart failure with reduced ejection fraction in a public safety-net hospital (RGDMT-HF study)
Doctor D. Zhuo (Atlanta, US)
Abstract Slides Video
Presentation thumbnail
Early impact of the implementation of the MAIC project and the UMIPIC programme on heart failure care in a secondary care setting
Doctor G. Ropero Luis (Ronda, Malaga, ES)
Abstract Slides Video
Presentation thumbnail
Beyond the pill: integrating multidisciplinary care team to implement individualised management strategies for patients with advanced heart failure
Mr K. Wong (Aberdeen, HK)
Abstract Slides Video

Access the full session

Session thumbnail
Implementing integrated care pathways in heart failure

The Event

Event poster

Heart Failure 2026

9 May 2026 11:30 CET
You may be interested in
thumbnail
Congress Presentation
Evaluation of cardiac MRI parameters during mavacamten treatment in obstructive hypertrophic cardiomyopathy: three- and six-month results
thumbnail
Congress Presentation
Reduction of >100 mmHg left ventricular outflow tract gradients in obstructive hypertrophic cardiomyopathy during mavacamten treatment already after one week of treatment
thumbnail
Congress Presentation
Systematic evaluation of serial electrocardiographic changes in patients treated with mavacamten

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources